Britannia Life Sciences Inc.
BLAB
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -41.81% | 169.67% | -60.98% | -52.79% | 7.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -41.81% | 169.67% | -60.98% | -52.79% | 7.82% |
| Cost of Revenue | -43.60% | -54.40% | -72.16% | -7.48% | 146.51% |
| Gross Profit | -33.17% | 99.76% | -41.89% | -75.55% | -71.65% |
| SG&A Expenses | -5.98% | -99.97% | -39.88% | 105.78% | -11.20% |
| Depreciation & Amortization | -1.77% | 5.61% | 3.67% | 4.55% | 5.61% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.83% | -82.75% | -43.37% | 82.18% | 7.58% |
| Operating Income | 3.67% | 98.34% | 38.59% | -236.16% | -7.47% |
| Income Before Tax | 268.96% | 217.12% | 4,237.85% | 71.55% | 25.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 268.96% | 280.01% | 3,684.19% | 71.55% | 25.05% |
| Earnings from Discontinued Operations | -- | -97.37% | 519.76% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 268.96% | -60.46% | 8,995.09% | 65.91% | 7.42% |
| EBIT | 3.67% | 98.34% | 38.59% | -236.16% | -7.47% |
| EBITDA | 3.75% | 99.88% | 39.67% | -254.47% | -7.55% |
| EPS Basic | 267.74% | -60.34% | 9,033.33% | 66.67% | 6.06% |
| Normalized Basic EPS | 106.06% | 125.53% | 75.00% | 68.75% | -127.59% |
| EPS Diluted | 267.74% | -60.34% | 9,033.33% | 66.67% | 6.06% |
| Normalized Diluted EPS | 106.06% | 125.53% | 75.00% | 68.75% | -127.59% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |